Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2019 | Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes | Tan T.Z.; Ye J.; Yee C.V.; Lim D.; Ngoi N.Y.L.; Tan D.S.P.; RUBY YUN-JU HUANG | EBioMedicine | 40 | 39 | |
2015 | The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions | Davidson B.; Holth A.; Hellesylt E.; Tan T.Z.; RUBY YUN-JU HUANG ; Trop? C.; Nesland J.M.; Thiery J.P. | Human Pathology | 49 | 45 | |
2016 | A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets | Jia D.; Liu Z.; Deng N.; Tan T.Z.; RUBY YUN-JU HUANG ; Taylor-Harding B.; Cheon D.-J.; Lawrenson K.; Wiedemeyer W.R.; Walts A.E.; Karlan B.Y.; Orsulic S. | Cancer Letters | 83 | 76 | |
2015 | CSIOVDB: A microarray gene expression database of epithelial ovarian cancer subtype | Tan T.Z.; Yang H.; Ye J.; Low J.; Choolani M.; Peng Tan D.S.; Thiery J.-P.; RUBY YUN-JU HUANG | Oncotarget | 64 | 59 | |
2020 | Cytoskeletal proteins in cancer and intracellular stress: A therapeutic perspective | Ong M.S.; Deng S.; Halim C.E.; Cai W.; Tan T.Z.; RUBY YUN-JU HUANG ; Sethi G.; Hooi S.C.; Kumar A.P.; Yap C.T. | Cancers | 57 | 54 | |
2019 | Decoding transcriptomic intra-tumour heterogeneity to guide personalised medicine in ovarian cancer | Tan T.Z.; Heong V.; Ye J.; Lim D.; Low J.; Choolani M.; Scott C.; Tan D.S.P.; RUBY YUN-JU HUANG | Journal of Pathology | 14 | 12 | |
2020 | Development and validation of the gene expression predictor of high-grade serous ovarian carcinoma molecular SubTYPE (PrOTYPE) | Talhouk A.; George J.; Wang C.; Budden T.; Tan T.Z.; Chiu D.S.; Kommoss S.; Leong H.S.; Chen S.; Intermaggio M.P.; Gilks B.; Nazeran T.M.; Volchek M.; Elatre W.; Bentley R.C.; Senz J.; Lum A.; Chow V.; Sudderuddin H.; Mackenzie R.; Leong S.C.Y.; Liu G.; Johnson D.; Chen B.; Alsop J.; Banerjee S.N.; Behrens S.; Bodelon C.; Brand A.H.; Brinton L.; Carney M.E.; Chiew Y.-E.; Cushing-Haugen K.L.; Cybulski C.; Ennis D.; Fereday S.; Fortner R.T.; Garc?a-Donas J.; Gentry-Maharaj A.; Glasspool R.; Goranova T.; Greene C.S.; Haluska P.; Harris H.R.; Hendley J.; Hernandez B.Y.; Herpel E.; Jimenez-Linan M.; Karpinskyj C.; Kaufmann S.H.; Keeney G.L.; Kennedy C.J.; Kobel M.; Koziak J.M.; Larson M.C.; Lester J.; Lewsley L.-A.; Lissowska J.; Lubi?ski J.; Luk H.; Macintyre G.; Mahner S.; McNeish I.A.; Menkiszak J.; Nevins N.; Osorio A.; Oszurek O.; Palacios J.; Hinsley S.; Pearce C.L.; Pike M.C.; Piskorz A.M.; Ray-Coquard I.; Rhenius V.; Rodriguez-Antona C.; Sharma R.; Sherman M.E.; de Silva D.; Singh N.; Sinn P.; Slamon D.; Song H.; Steed H.; Stronach E.A.; Thompson P.J.; To?oczko A.; Trabert B.; Traficante N.; Tseng C.-C.; Widschwendter M.; Wilkens L.R.; Winham S.J.; Winterhoff B.; Beeghly-Fadiel A.; Benitez J.; Berchuck A.; Brenton J.D.; Brown R.; Chang-Claude J.; Chenevix-Trench G.; deFazio A.; Fasching P.A.; Garc?a M.J.; Gayther S.A.; Goodman M.T.; Gronwald J.; Henderson M.J.; Karlan B.Y.; Kelemen L.E.; Menon U.; Orsulic S.; Pharoah P.D.P.; Wentzensen N.; Wu A.H.; Schildkraut J.M.; Rossing M.A.; Konecny G.E.; Huntsman D.G.; RUBY YUN-JU HUANG ; Goode E.L.; Ramus S.J.; Doherty J.A.; Bowtell D.D.; Anglesio M.S.; AOCS Group | Clinical Cancer Research | 37 | 33 | |
2018 | Dual role of autophagy in hallmarks of cancer | Singh S.S.; Vats S.; Chia A.Y.-Q.; Tan T.Z.; Deng S.; Ong M.S.; Arfuso F.; Yap C.T.; Goh B.C.; Sethi G.; RUBY YUN-JU HUANG ; Shen H.M.; Manjithaya R.; Kumar A.P. | Oncogene | 389 | 354 | |
2013 | An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530) | RUBY YUN-JU HUANG ; Wong M.K.; Tan T.Z.; Kuay K.T.; C Ng A.H.; Chung V.Y.; Chu Y.-S.; Matsumura N.; Lai H.-C.; Lee Y.F.; Sim W.-J.; Chai C.; Pietschmann E.; Mori S.; Low J.J.H.; Choolani M.; Thiery J.P. | Cell Death and Disease | 316 | 290 | |
2014 | Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients | Tan T.Z.; Miow Q.H.; Miki Y.; Noda T.; Mori S.; RUBY YUN-JU HUANG ; Thiery J.P. | EMBO Molecular Medicine | 481 | 455 | |
2020 | Erratum: Author Correction: Single-cell analysis of EphA clustering phenotypes to probe cancer cell heterogeneity (Communications biology (2020) 3 1 (429)) | Ravasio A.; Myaing M.Z.; Chia S.; Arora A.; Sathe A.; Cao E.Y.; Bertocchi C.; Sharma A.; Arasi B.; Chung V.Y.; Greene A.C.; Tan T.Z.; Chen Z.; Ong H.T.; Iyer N.G.; RUBY YUN-JU HUANG ; DasGupta R.; Groves J.T.; Viasnoff V. | Communications biology | 0 | 1 | |
2013 | Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer | Tan T.Z.; Miow Q.H.; RUBY YUN-JU HUANG ; Wong M.K.; Ye J.; Lau J.A.; Wu M.C.; Bin Abdul Hadi L.H.; Soong R.; Choolani M.; Davidson B.; Nesland J.M.; Wang L.-Z.; Matsumura N.; Mandai M.; Konishi I.; Goh B.-C.; Chang J.T.; Thiery J.P.; Mori S. | EMBO Molecular Medicine | 159 | 151 | |
2015 | Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120) | RUBY YUN-JU HUANG ; Kuay K.T.; Tan T.Z.; Asad M.; Tang H.M.; Chun Ng A.H.; Ye J.; Chung V.Y.; Thiery J.P. | Oncotarget | 40 | 38 | |
2019 | The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma | Tan M.; Asad M.; Heong V.; Wong M.K.; Tan T.Z.; Ye J.; Kuay K.T.; Thiery J.P.; Scott C.; RUBY YUN-JU HUANG | Molecular Oncology | 17 | 14 | |
2016 | The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer | Antony J.; Tan T.Z.; Kelly Z.; Low J.; Choolani M.; Recchi C.; Gabra H.; Thiery J.P.; RUBY YUN-JU HUANG | Science Signaling | 91 | 91 | |
2016 | GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification | Chung V.Y.; Tan T.Z.; Tan M.; Wong M.K.; Kuay K.T.; Yang Z.; Ye J.; Muller J.; Koh C.M.; Guccione E.; Thiery J.P.; RUBY YUN-JU HUANG | Scientific Reports | 114 | 106 | |
2020 | Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma | Yabuno A.; Matsushita H.; Hamano T.; Tan T.Z.; Shintani D.; Fujieda N.; Tan D.S.P.; RUBY YUN-JU HUANG ; Fujiwara K.; Kakimi K.; Hasegawa K. | Scientific Reports | 4 | 3 | |
2020 | Inflammatory and mitogenic signals drive interleukin 23 subunit alpha (IL23A) secretion independent of IL12B in intestinal epithelial cells | Lim K.S.; Ern Yong Z.W.; Wang H.; Tan T.Z.; RUBY YUN-JU HUANG ; Yamamoto D.; Inaki N.; Hazawa M.; Wong R.W.; Oshima H.; Oshima M.; Ito Y.; Chih-Cheng Voon X.D. | Journal of Biological Chemistry | 19 | 18 | |
2014 | Lgr5 marks stem/progenitor cells in ovary and tubal epithelia | Ng A.; Tan S.; Singh G.; Rizk P.; Swathi Y.; Tan T.Z.; RUBY YUN-JU HUANG ; Leushacke M.; Barker N. | Nature Cell Biology | 168 | 157 | |
2017 | ‘Lnc’-ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signalling | Ong M.S.; Cai W.; Yuan Y.; Leong H.C.; Tan T.Z.; Mohammad A.; You M.L.; Arfuso F.; Goh B.C.; Warrier S.; Sethi G.; Tolwinski N.S.; Lobie P.E.; Yap C.T.; Hooi S.C.; RUBY YUN-JU HUANG ; Kumar A.P. | British Journal of Pharmacology | 57 | 56 |